- Home
- REGN vs INFY Comparison
REGN vs INFY Comparison
Compare REGN & INFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- INFY
- Stock Information
- Founded
- REGN 1988
- INFY 1981
- Country
- REGN United States
- INFY India
- Employees
- REGN N/A
- INFY N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- INFY EDP Services
- Sector
- REGN Health Care
- INFY Technology
- Exchange
- REGN Nasdaq
- INFY Nasdaq
- Market Cap
- REGN 63.4B
- INFY 96.0B
- IPO Year
- REGN 1991
- INFY 1999
- Fundamental
- Price
- REGN $547.67
- INFY $17.49
- Analyst Decision
- REGN Buy
- INFY Hold
- Analyst Count
- REGN 23
- INFY 7
- Target Price
- REGN $907.39
- INFY $17.33
- AVG Volume (30 Days)
- REGN 1.2M
- INFY 12.4M
- Earning Date
- REGN 04-29-2025
- INFY 04-17-2025
- Dividend Yield
- REGN 0.32%
- INFY 2.69%
- EPS Growth
- REGN 16.49
- INFY N/A
- EPS
- REGN 39.43
- INFY 0.76
- Revenue
- REGN $14,085,700,000.00
- INFY $19,277,000,000.00
- Revenue This Year
- REGN $2.38
- INFY $6.94
- Revenue Next Year
- REGN $7.65
- INFY $7.41
- P/E Ratio
- REGN $14.23
- INFY $23.16
- Revenue Growth
- REGN 7.52
- INFY 3.85
- 52 Week Low
- REGN $520.50
- INFY $15.82
- 52 Week High
- REGN $1,211.20
- INFY $23.63
- Technical
- Relative Strength Index (RSI)
- REGN 38.69
- INFY 47.44
- Support Level
- REGN $542.44
- INFY $17.29
- Resistance Level
- REGN $615.61
- INFY $17.99
- Average True Range (ATR)
- REGN 22.06
- INFY 0.26
- MACD
- REGN -0.13
- INFY 0.14
- Stochastic Oscillator
- REGN 28.57
- INFY 67.48
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About INFY Infosys Limited
Infosys is a leading global IT services provider, with nearly 250,000 employees. Based in Bangalore, the Indian IT services firm leverages its offshore outsourcing model to derive 60% of its revenue from North America. The company offers traditional IT services offerings: consulting, managed services and cloud infrastructure services, and business process outsourcing as a service (BPaaS).